Patents by Inventor Michael VanAuker

Michael VanAuker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8435558
    Abstract: A method of targeted drug delivery and imaging using nonionic surfactant vesicles (niosomes) in combination with ultrasound is presented. Niosomes have potential applications in targeted drug delivery and imaging because of their ability to encapsulate therapeutic agents and their enhanced uptake by physiological membranes. The niosomes may be administered to the subject via catheter. Ultrasound may be used to mediate delivery non-invasively by altering the niosome membrane structure. Niosomes composed of polyoxyethylene sorbitan monostearate (Tween 61), cholesterol, and dicetyl phosphate were synthesized via a thin film hydration technique and used for encapsulation studies. Carboxyfluorescein dye (CF) was used as a drug model to demonstrate delivery. The amount of dye in the niosomes, the concentration of the vesicles, and their mean particle size after each 5 minute incremental exposure to ultrasound was monitored.
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: May 7, 2013
    Assignee: University of South Florida
    Inventors: Elizabeth Hood, Joel A. Strom, Michael VanAuker
  • Patent number: 7981442
    Abstract: A method of targeted drug delivery and imaging using nonionic surfactant vesicles (niosomes) in combination with ultrasound. Niosomes have potential applications in targeted drug delivery and imaging because of their ability to encapsulate therapeutic agents and their enhanced uptake by physiological membranes. Ultrasound may be used to mediate delivery non-invasively by altering the niosome membrane structure. Niosomes composed of polyoxyethylene sorbitan monostearate (Tween 61), cholesterol, and dicetyl phosphate were synthesized via a thin film hydration technique and used for encapsulation studies. Carboxyfluorescein dye (CF) was used as a drug model to demonstrate delivery. The amount of dye in the niosomes, the concentration of the vesicles, and their mean particle size after each 5 minute incremental exposure to ultrasound was monitored. Dye concentration in niosome samples decreased while the population and size distribution of the niosome remained largely unchanged.
    Type: Grant
    Filed: June 28, 2006
    Date of Patent: July 19, 2011
    Assignee: University of South Florida
    Inventors: Elizabeth Hood, Joel A. Strom, Michael VanAuker
  • Publication number: 20080050445
    Abstract: Taught herein is a drug-delivery system that includes encapsulating a therapeutic drug in a nanoparticle vesicle that is then embedded into a hydrogel network. The system allows for enhanced, two-fold control over the release rate of the drug. This technology will be particularly advantageous in treating malignant cancer cells such as those found in the brain. The invention will allow for decreased side effects and increased survival time in patients. This invention opens the door to other technological applications that require controlled release of chemical substances.
    Type: Application
    Filed: April 19, 2007
    Publication date: February 28, 2008
    Applicant: UNIVERSITY OF SOUTH FLORIDA
    Inventors: Norma Alcantar, Kristina Dearborn, Michael VanAuker, Ryan Toomey, Elizabeth Hood
  • Publication number: 20070172520
    Abstract: An immunoniosmes for targeted delivery of therapeutic agents to specific tissues in a host and methods of synthesis of those niosomes. An antibody molecule having specificity for a target antigen, such as a cell surface marker or other marker differentially expressed on a target cell, is covalently coupled to a functionalized membrane constituent. In a particular embodiment the functionalized membrane constituent is polyoxyethylene sorbitan monostearate functionalized with cyanuric chloride. The niosomes of this invention thus provide a composition that enhances internalization or retention of the bioactive agent of the niosome into the cytoplasm of the cells of the target tissue by providing a high degree of target specificity. Furthermore, the membrane vesicle enhances the life of the therapeutic agent by preventing its degradation in the extracellular environment, while exhibiting lower toxicity than can occur with some liposomes.
    Type: Application
    Filed: November 20, 2006
    Publication date: July 26, 2007
    Applicant: UNIVERSITY OF SOUTH FLORIDA
    Inventors: Michael VanAuker, Anna Plaas, Elizabeth Hood
  • Publication number: 20060292211
    Abstract: A method of targeted drug delivery and imaging using nonionic surfactant vesicles (niosomes) in combination with ultrasound. Niosomes have potential applications in targeted drug delivery and imaging because of their ability to encapsulate therapeutic agents and their enhanced uptake by physiological membranes. Ultrasound may be used to mediate delivery non-invasively by altering the niosome membrane structure. Niosomes composed of polyoxyethylene sorbitan monostearate (Tween 61), cholesterol, and dicetyl phosphate were synthesized via a thin film hydration technique and used for encapsulation studies. Carboxyfluorescein dye (CF) was used as a drug model to demonstrate delivery. The amount of dye in the niosomes, the concentration of the vesicles, and their mean particle size after each 5 minute incremental exposure to ultrasound was monitored. Dye concentration in niosome samples decreased while the population and size distribution of the niosome remained largely unchanged.
    Type: Application
    Filed: June 28, 2006
    Publication date: December 28, 2006
    Applicant: UNIVERSITY OF SOUTH FLORIDA
    Inventors: Elizabeth Hood, Joel Strom, Michael VanAuker